HPTN Publications

Lole K, Bollinger RC, Paranjape R, Gadkari D, Kulkarni S, Novak N, Ingersoll R, Sheppard H, Rau S . Full-length human immunodeficiency virus type 1 genomes from subtype c-infected seroconverters in India, with evidence of intersubtype recombination. J Virol. 1999, 73: 152-160

London AJ, Borasky DA Jr, Bhan A for the Ethics Working Group of the HIV Prevention Trials Network . Improving Ethical Review of Research Involving Incentives for Health Promotion. PLoS Med. 2012, 9: e1001193

London AJ, Borasky DA Jr, Bhan A; Ethics Working Group of the HIV Prevention Trials Network, Bhan A, Ethics Working Group of the HIV Prevention Trials Network . Improving ethical review of research involving incentives for health promotion. PLoS Med. 2012, 9: e1001193

Longosz AF, Mehta S, Kirk GD, Margolick JB, Brown J, Quinn TC, Eshleman SH, Laeyendecker O . Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay. AIDS. 2014, 28: 1227-32

Longosz AF, Morrison CS, Chen P-L, Arts E, Nankya I, Salata RA, Franco V, Quinn TC, Eshleman SH, Laeyendecker O, Chen PL . Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay. J Acquir Immune Defic Syndr. 2014, 65: 390-6

Longosz AF, Morrison CS, Chen PL, Brand HH, Arts E, Nankya I, Salata RA, Quinn TC, Eshleman SH, Laeyendecker O . Comparison of antibody responses to HIV infection in Ugandan women infected with HIV subtypes A and D. AIDS Res Hum Retroviruses. 2015, 31: 421-7

Longosz AF, Serwadda D, Nalugoda F, Kigozi G, Franco V, Gray RH, Quinn TC, Eshleman SH, Laeyendecker O . Impact of HIV subtype on performance of the limiting antigen-avidity enzyme immunoassay, the bio-rad avidity assay, and the BED capture immunoassay in Rakai, Uganda. AIDS Res Hum Retroviruses. 2014, 30: 339-44

Lu Y, Celum C, Wald A, Baeten JM, Cowan F, Delany-Moretlwe S, Reid SE, Hughes JP, Wilcox E, Corey L, Hendrix CW . Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations. Antimicrob Agents Chemother. 2012, 56: 2777-9